BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37004752)

  • 1. An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease.
    Liu X; Lai LY; Chen JX; Li X; Wang N; Zhou LJ; Jiang XW; Hu XL; Liu WW; Jiao XM; Qi ZT; Liu WJ; Wu LM; Huang YG; Xu ZH; Zhao QC
    Neuropharmacology; 2023 Jul; 232():109525. PubMed ID: 37004752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrogen sulfide is neuroprotective in Alzheimer's disease by sulfhydrating GSK3β and inhibiting Tau hyperphosphorylation.
    Giovinazzo D; Bursac B; Sbodio JI; Nalluru S; Vignane T; Snowman AM; Albacarys LM; Sedlak TW; Torregrossa R; Whiteman M; Filipovic MR; Snyder SH; Paul BD
    Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33431651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryptotanshinone Attenuates Amyloid-β
    Lyu D; Jia J
    Mol Neurobiol; 2022 Jul; 59(7):4488-4500. PubMed ID: 35575872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel harmine derivatives as GSK-3β/DYRK1A dual inhibitors for Alzheimer's disease treatment.
    Qiu J; Feng X; Chen H; Liu W; Liu W; Wu L; Gao X; Liu Y; Huang Y; Gong H; Qi Y; Xu Z; Zhao Q
    Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300404. PubMed ID: 38010470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
    Fan SJ; Huang FI; Liou JP; Yang CR
    Cell Death Dis; 2018 May; 9(6):655. PubMed ID: 29844403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Okadaic acid-induced Tau phosphorylation in rat brain: role of NMDA receptor.
    Kamat PK; Rai S; Swarnkar S; Shukla R; Ali S; Najmi AK; Nath C
    Neuroscience; 2013 May; 238():97-113. PubMed ID: 23415789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GSK3β inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease.
    Koehler D; Shah ZA; Williams FE
    Neurochem Int; 2019 Jan; 122():31-37. PubMed ID: 30392874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3β activity in SH-SY5Y cells.
    Wu X; Kosaraju J; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():101-108. PubMed ID: 28359686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystatin C promotes tau protein phosphorylation and causes microtubule instability by inhibiting intracellular turnover of GSK3β in neurons.
    Duan J; Marcellus KA; Qin X; Wang Y; Paudel HK
    Mol Cell Neurosci; 2018 Jun; 89():1-8. PubMed ID: 29577984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice.
    Hu Y; Lai J; Wan B; Liu X; Zhang Y; Zhang J; Sun D; Ruan G; Liu E; Liu GP; Chen C; Wang DW
    Neurotoxicology; 2016 Mar; 53():290-300. PubMed ID: 26945731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protective effects of Esculentoside A through AMPK in the triple transgenic mouse model of Alzheimer's disease.
    He Z; Zhang H; Li X; Tu S; Wang Z; Han S; Du X; Shen L; Li N; Liu Q
    Phytomedicine; 2023 Jan; 109():154555. PubMed ID: 36610160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.
    Pradeepkiran JA; Munikumar M; Reddy AP; Reddy PH
    Hum Mol Genet; 2021 Dec; 31(2):244-261. PubMed ID: 34432046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3β.
    Martin L; Page G; Terro F
    Neurochem Int; 2011 Aug; 59(2):235-50. PubMed ID: 21672577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GRK5 influences the phosphorylation of tau via GSK3β and contributes to Alzheimer's disease.
    Zhao J; Li X; Chen X; Cai Y; Wang Y; Sun W; Mai H; Yang J; Fan W; Tang P; Ou M; Zhang Y; Huang X; Zhao B; Cui L
    J Cell Physiol; 2019 Jul; 234(7):10411-10420. PubMed ID: 30511419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement C3a receptor antagonist attenuates tau hyperphosphorylation via glycogen synthase kinase 3β signaling pathways.
    Hu J; Yang Y; Wang M; Yao Y; Chang Y; He Q; Ma R; Li G
    Eur J Pharmacol; 2019 May; 850():135-140. PubMed ID: 30771350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidins220 accumulates with tau in human Alzheimer's disease and related models: modulation of its calpain-processing by GSK3β/PP1 imbalance.
    López-Menéndez C; Gamir-Morralla A; Jurado-Arjona J; Higuero AM; Campanero MR; Ferrer I; Hernández F; Ávila J; Díaz-Guerra M; Iglesias T
    Hum Mol Genet; 2013 Feb; 22(3):466-82. PubMed ID: 23118350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Okadaic acid-induced tau hyperphosphorylation and the downregulation of Pin1 expression in primary cortical neurons.
    Metin-Armağan D; Gezen-Ak D; Dursun E; Atasoy İL; Karabay A; Yılmazer S; Öztürk M
    J Chem Neuroanat; 2018 Oct; 92():41-47. PubMed ID: 29860071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.